Suppr超能文献

系统炎症和身体状况不佳与老年癌症患者生存结局降低有关。

Association of systemic inflammation and low performance status with reduced survival outcome in older adults with cancer.

机构信息

Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, PR China; Key Laboratory of Cancer FSMP for State Market Regulation, Beijing, 100038, PR China.

Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region 530021, PR China; Guangxi Clinical Research Center for Colorectal Cancer, Nanning, Guangxi Zhuang Autonomous Region 530021, PR China.

出版信息

Clin Nutr. 2022 Oct;41(10):2284-2294. doi: 10.1016/j.clnu.2022.08.025. Epub 2022 Aug 29.

Abstract

BACKGROUND

Inflammation is involved in the progression and prognosis of cancer because it can affect the physical status and prognosis of patients. Among numerous systemic inflammatory markers, the optimal prognostic indicator of older adults with cancer is still unclear. We aimed to identify an ideal inflammatory immune marker in older adults with cancer and assess the survival outcome combined with eastern cooperative oncology group performance status (ECOG PS).

METHODS

We included 1767 older adults with cancer (66.2% males, 70.97 ± 5.49 years old) from a prospective cohort study. Fifteen systemic inflammatory biomarkers were compared to identify the optimal biomarker using prognostic area under the curve (AUC) and concordance index (C-index) analysis. The prognostic value of the clinical parameters was elucidated by performing uni- and multivariate analyses.

RESULTS

The AUC, C-index, and the subgroup survival analysis of ECOG PS groups showed that the lymphocyte-C reactive protein ratio (LCR) and C-reactive protein/albumin ratio (CAR) were more accurate in reflecting patient prognosis than the other 13 inflammatory markers. Compared with patients in the high LCR group, those in the low LCR group had worse survival (hazard ratio (HR) 1.64, 95% confidence interval (95%CI) 1.42-1.91, p < 0.001). Compared with patients in the low CAR group, those in the high CAR group had worse survival (HR 1.65, 95% CI 1.43-1.91, p < 0.001). Older adults with cancer with an ECOG PS score of 2 or 3-4 and a high inflammation (low LCR, 13.3 months and 9.2 months, respectively; or high CAR, 9.6 months and 9.6 months, respectively) had shorter median survival time compared to those with an ECOG PS score of 0/1 and a low inflammation (high LCR, 77.4 months; or low CAR, 77.0 months).

CONCLUSION

LCR and CAR might be the better predictive immune inflammatory factors for OS, which improved the survival prediction of different ECOG PS groups in older adults with cancer. High ECOG PS (≥2) and high inflammation increased the risk of death in older adults with cancer.

摘要

背景

炎症参与癌症的进展和预后,因为它会影响患者的身体状况和预后。在众多全身性炎症标志物中,癌症老年患者的最佳预后指标仍不清楚。我们旨在确定癌症老年患者中理想的炎症免疫标志物,并结合东部合作肿瘤组表现状态(ECOG PS)评估生存结局。

方法

我们纳入了一项前瞻性队列研究中的 1767 名癌症老年患者(66.2%为男性,70.97±5.49 岁)。通过预后曲线下面积(AUC)和一致性指数(C-index)分析比较了 15 种系统性炎症生物标志物,以确定最佳标志物。通过单变量和多变量分析阐明了临床参数的预后价值。

结果

AUC、C-index 和 ECOG PS 组的亚组生存分析显示,淋巴细胞- C 反应蛋白比值(LCR)和 C 反应蛋白/白蛋白比值(CAR)比其他 13 种炎症标志物更能准确反映患者的预后。与 LCR 高组患者相比,LCR 低组患者的生存情况更差(风险比(HR)1.64,95%置信区间(95%CI)1.42-1.91,p<0.001)。与 CAR 低组患者相比,CAR 高组患者的生存情况更差(HR 1.65,95%CI 1.43-1.91,p<0.001)。ECOG PS 评分为 2 或 3-4 分且炎症程度高(低 LCR 分别为 13.3 个月和 9.2 个月;或高 CAR,分别为 9.6 个月和 9.6 个月)的癌症老年患者的中位生存时间短于 ECOG PS 评分为 0/1 分且炎症程度低(高 LCR,77.4 个月;或低 CAR,77.0 个月)的患者。

结论

LCR 和 CAR 可能是 OS 的更好预测免疫炎症因素,可改善不同 ECOG PS 组癌症老年患者的生存预测。高 ECOG PS(≥2)和高炎症增加了癌症老年患者的死亡风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验